NEUTRA CORP. (NTRR)
D
Pipeline Grade
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase3 Readout | — |
| 2026-09-01 | Phase3 Readout | — |
| 2026-10-31 | Phase3 Readout | — |
| 2026-11-01 | Phase3 Readout | — |
| 2027-01-30 | Phase3 Readout | — |
| 2027-07-02 | Phase3 Readout | — |
Active Clinical Trials (17)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06383390 | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIU... | PHASE3 | Active Not Recruiting | 10,000 |
| NCT05030428 | Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | PHASE3 | Active Not Recruiting | 17,004 |
| NCT06588855 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants... | PHASE3 | Recruiting | 350 |
| NCT05739383 | A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | PHASE3 | Active Not Recruiting | 14,012 |
| NCT06935370 | A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a ... | PHASE3 | Recruiting | 4,200 |
| NCT05636176 | A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | PHASE3 | Active Not Recruiting | 4,899 |
| NCT06430801 | A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Di... | PHASE3 | Recruiting | 1,200 |
| NCT06052059 | A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulc... | PHASE3 | Active Not Recruiting | 1,020 |
| NCT02914535 | Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis | PHASE3 | Active Not Recruiting | 1,173 |
| NCT05757869 | A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | PHASE3 | Active Not Recruiting | 20,284 |
| NCT04023552 | Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients Wit... | PHASE3 | Active Not Recruiting | 8,323 |
| NCT05581303 | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial | PHASE3 | Active Not Recruiting | 7,297 |
| NCT07517263 | An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerabilit... | PHASE3 | Recruiting | 5,700 |
| NCT06292013 | A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With ... | PHASE3 | Active Not Recruiting | 17,300 |
| NCT06819891 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderate... | PHASE3 | Recruiting | 425 |
| NCT05202509 | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | PHASE3 | Active Not Recruiting | 9,541 |
| NCT07037433 | Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov... | PHASE3 | Recruiting | 12,800 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.